AU2017359607A1 - Compositions for the treatment of hypertension - Google Patents

Compositions for the treatment of hypertension Download PDF

Info

Publication number
AU2017359607A1
AU2017359607A1 AU2017359607A AU2017359607A AU2017359607A1 AU 2017359607 A1 AU2017359607 A1 AU 2017359607A1 AU 2017359607 A AU2017359607 A AU 2017359607A AU 2017359607 A AU2017359607 A AU 2017359607A AU 2017359607 A1 AU2017359607 A1 AU 2017359607A1
Authority
AU
Australia
Prior art keywords
dose
pharmaceutical composition
diuretic
blocker
hypertension therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017359607A
Other languages
English (en)
Inventor
Clara Chow
Anthony Rodgers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sydney
George Institute for Global Health
Original Assignee
University of Sydney
George Institute for Global Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sydney, George Institute for Global Health filed Critical University of Sydney
Publication of AU2017359607A1 publication Critical patent/AU2017359607A1/en
Priority to AU2023258387A priority Critical patent/AU2023258387B2/en
Priority to AU2025210908A priority patent/AU2025210908A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017359607A 2016-11-15 2017-11-14 Compositions for the treatment of hypertension Abandoned AU2017359607A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023258387A AU2023258387B2 (en) 2016-11-15 2023-11-01 Compositions for the treatment of hypertension
AU2025210908A AU2025210908A1 (en) 2016-11-15 2025-08-04 Compositions for the treatment of hypertension

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/352,425 US10369156B2 (en) 2016-11-15 2016-11-15 Compositions for the treatment of hypertension
US15/352,425 2016-11-15
PCT/IB2017/001524 WO2018091967A1 (en) 2016-11-15 2017-11-14 Compositions for the treatment of hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023258387A Division AU2023258387B2 (en) 2016-11-15 2023-11-01 Compositions for the treatment of hypertension

Publications (1)

Publication Number Publication Date
AU2017359607A1 true AU2017359607A1 (en) 2019-06-06

Family

ID=62107049

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017359607A Abandoned AU2017359607A1 (en) 2016-11-15 2017-11-14 Compositions for the treatment of hypertension
AU2023258387A Active AU2023258387B2 (en) 2016-11-15 2023-11-01 Compositions for the treatment of hypertension
AU2025210908A Pending AU2025210908A1 (en) 2016-11-15 2025-08-04 Compositions for the treatment of hypertension

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023258387A Active AU2023258387B2 (en) 2016-11-15 2023-11-01 Compositions for the treatment of hypertension
AU2025210908A Pending AU2025210908A1 (en) 2016-11-15 2025-08-04 Compositions for the treatment of hypertension

Country Status (8)

Country Link
US (2) US10369156B2 (enExample)
EP (2) EP4574136A3 (enExample)
JP (3) JP2019536816A (enExample)
CN (2) CN110366414A (enExample)
AU (3) AU2017359607A1 (enExample)
CA (1) CA3043835A1 (enExample)
TW (1) TWI799397B (enExample)
WO (1) WO2018091967A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
AU2018213147B2 (en) 2017-01-25 2023-08-31 The George Institute for Global Health Compositions for the treatment of hypertension
AU2019285170A1 (en) * 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
JP2021528735A (ja) * 2018-06-14 2021-10-21 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ アンジオテンシンｉｉ受容体遮断薬医薬組成物による高血圧症の治療方法
BR112021001374A2 (pt) * 2018-07-26 2021-07-06 The George Inst For Global Health composições para o tratamento da hipertensão
JP2021536443A (ja) * 2018-08-25 2021-12-27 シーアールディー ファーマシューティカルズ インコーポレイティド 高血圧治療をサーカディアンリズムと同期させる
EP4649946A1 (en) * 2024-05-16 2025-11-19 Alba Research S.r.l. Compositions for treating arterial hypertension

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272220B2 (en) 2000-04-10 2016-07-27 Nicholas John Wald Formulation for the prevention of cardiovascular disease
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
EP1353727A2 (en) * 2000-12-01 2003-10-22 Novartis AG Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2005070462A2 (en) 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
EP1734958A1 (en) * 2004-04-06 2006-12-27 Merck & Co., Inc. Methods for the treatment of hypertension
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
JP2009256209A (ja) * 2006-02-17 2009-11-05 Gilead Colorado Inc 降圧療法
WO2007146900A2 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
CN101450211A (zh) 2007-12-07 2009-06-10 上海艾力斯医药科技有限公司 复方降压制剂
WO2011149438A1 (en) 2010-05-28 2011-12-01 Mahmut Bilgic Combination of antihypertensive agents
CN101966190A (zh) 2010-07-17 2011-02-09 邬林祥 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂
CN102225203A (zh) 2011-06-29 2011-10-26 北京阜康仁生物制药科技有限公司 一种用于降低血压的药用组合物
US10918612B2 (en) 2013-01-22 2021-02-16 Markus Zwickl Combinations with 2-aminoethanesulfonic acid
CN106310278A (zh) 2016-08-01 2017-01-11 深圳奥萨制药有限公司 一种含叶酸的多联降压药物组合物
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
AU2018213147B2 (en) 2017-01-25 2023-08-31 The George Institute for Global Health Compositions for the treatment of hypertension

Also Published As

Publication number Publication date
AU2025210908A1 (en) 2025-08-21
EP4574136A3 (en) 2025-09-17
TW201828988A (zh) 2018-08-16
WO2018091967A1 (en) 2018-05-24
CN116603066A (zh) 2023-08-18
CN110366414A (zh) 2019-10-22
AU2023258387B2 (en) 2025-05-29
US10369156B2 (en) 2019-08-06
JP2025102796A (ja) 2025-07-08
US20180133227A1 (en) 2018-05-17
AU2023258387A1 (en) 2023-11-23
EP3541379A4 (en) 2020-05-27
BR112019009859A2 (pt) 2019-08-20
JP2023095844A (ja) 2023-07-06
TWI799397B (zh) 2023-04-21
US20190314383A1 (en) 2019-10-17
EP3541379A1 (en) 2019-09-25
JP2019536816A (ja) 2019-12-19
CA3043835A1 (en) 2018-05-24
EP4574136A2 (en) 2025-06-25

Similar Documents

Publication Publication Date Title
AU2023258387B2 (en) Compositions for the treatment of hypertension
US12285415B2 (en) Compositions for the treatment of hypertension
HK40106299A (en) Compositions for the treatment of hypertension
BR112019009859B1 (pt) Composição farmacêutica para o tratamento de hipertensão e uso da mesma
BR122024023236A2 (pt) Composição farmacêutica para o tratamento de hipertensão e uso da mesma

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted